Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 277.33 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alnylam Pharmaceuticals < Previous 1 2 ... 8 9 10 11 12 13 14 15 Next > The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates April 28, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Alnylam Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Period Activity April 28, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire What To Know About Morgan Stanley's Downgrade of Alnylam Pharmaceuticals April 25, 2022 Morgan Stanley downgraded its rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) to Equal-Weight with a price target of $178.00, changing its price target from $210.00 to $178.00. Shares of Alnylam... Via Benzinga Analyst Ratings for Alnylam Pharmaceuticals April 12, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings within the last quarter: Via Benzinga See Why Did FDA Extend Review Period For Alnylam's Vutrisiran In Amyloidosis April 04, 2022 Via Benzinga Earnings Scheduled For February 10, 2022 February 10, 2022 Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022 April 25, 2022 Via Benzinga The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More April 24, 2022 Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... Via Benzinga 7 Potential Biotech Stocks Buyout Targets in 2022 April 21, 2022 Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. Via InvestorPlace Alnylam Pharmaceuticals Q1 2022 Earnings Conference Call On April 28, 2022 At 08:30 AM ET April 19, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) will host a conference call at 08:30 AM ET on April 28, 2022, to discuss Q1 2022 earnings results. Via Benzinga Alnylam to Webcast Conference Call Discussing First Quarter 2022 Financial Results April 14, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces Retirement of Steven Paul, M.D. from Board of Directors April 05, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Announces 3-Month Extension of Review Period for New Drug Application for Vutrisiran April 04, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates April 01, 2022 Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... Via Benzinga Alnylam to Webcast Presentation at Stifel 2022 CNS Days March 22, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire World Markets News For Friday March 18, 2022 Buoyant global markets are closing the week and one good performer, Vir Biotech, today gained an impressive 6.09%. Via Talk Markets Maker Of Pfizer's COVID-19 Vaccine mRNA-Delivery Tech Sues Arbutus Biopharma: Reuters March 18, 2022 Canada-based Acuitas Therapeutics Inc has sued Arbutus Biopharma Corporation (NASDAQ: ABUS) in Manhattan federal court, seeking to head off claims that the vaccine infringes Arbutus' patents, Via Benzinga Alnylam Hits Pfizer, Moderna With Patent Infringement Suits March 17, 2022 Via Benzinga Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna March 17, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam Issues 2021 Corporate Responsibility Report March 16, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire What 8 Analyst Ratings Have To Say About Alnylam Pharmaceuticals March 01, 2022 Within the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Alnylam Debuts New Documentary, Two of Me: Living with Porphyria, to Help Shorten Time to Diagnosis for Acute Hepatic Porphyria (AHP) February 28, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022 March 01, 2022 Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... Via Benzinga Looking Into Alnylam Pharmaceuticals's Return On Capital Employed February 11, 2022 Benzinga Pro data, Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 sales of $258.54 million. Earnings fell to a loss of $258.46 million, resulting in a 26.38% decrease from last quarter. Via Benzinga Expert Ratings For Alnylam Pharmaceuticals February 11, 2022 Analysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish... Via Benzinga Alnylam Clocks 76% Increase In Q4 Product Sales, Expects FY22 Product Sales Of Up To $1B February 10, 2022 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) Via Benzinga The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly February 10, 2022 Here's a roundup of top developments in the biotech space over the last 24 hours: Via Benzinga Alnylam Pharmaceuticals: Q4 Earnings Insights February 10, 2022 Alnylam Pharmaceuticals (NASDAQ:ALNY) reported its Q4 earnings results on Thursday, February 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Via Benzinga Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Period Activity February 10, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire Alnylam to Webcast Presentation at 11th Annual SVB Leerink Global Healthcare Conference February 08, 2022 From Alnylam Pharmaceuticals, Inc. Via Business Wire < Previous 1 2 ... 8 9 10 11 12 13 14 15 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.